Schizophrenia/Psychosis

How can the best insights of mainstream and critical psychiatry be brought together?

The RISE study results look promising.

There is much to look forward to in the realm of improved treatments for patients with psychiatric illness.

Our basic science knowledge of the brain continues to explode beyond what science fiction of the past has predicted.

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Navigating the treatment options for comorbid schizophrenia and alcohol use

Findings bring us closer to understanding schizophrenia that may enable clinicians to target symptoms.

Karuna Therapeutics shared exciting results from a Phase 2 trial on their lead agent.

Mutations in PCM1, a gene crucial to neuronal cilia function, have been connected with schizophrenia, according to a recent study.

Listen to discussion on results from a recent Phase 1b clinical trial.

Joining together to discuss psychosis, 3 British experts discuss various ways to respond to and help people who have experienced both trauma and psychosis.

A recent drug trial yields encouraging results.

COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.

Recent research sheds light on the role of adjunctive long-acting injectable antipsychotics in treatment-resistant schizophrenia.

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.

New research underlies the need for addressing identity in young patients during early stages of psychosis.

An explanation for the clinical presentation of delusions and hallucinations may have just been found.

More than 50% of patients with schizophrenia are estimated to be nonadherent with their antipsychotic medication regimen. What treatment solutions are available?

Data from a randomized phase III trial shows promise for new treatment strategy.

Researchers investigated in-hospital mortality and ICU admission in patients with COVID-19 with and without comorbid schizophrenia in a population-based cohort study.

A new, unique long-acting injectable for treating schizophrenia may be on the way.

When switching to this long-acting injectable antipsychotic, how long should an oral pre-switch antipsychotic be continued? Find out in this quiz.

This case illustrates the practical implications and effectiveness of the Minnesota Multiphasic Personality Inventory-2 in documenting patient recovery during treatment for delusional disorder.

Alkermes plc’s new drug, ALKS 3831, pending FDA approval, could be helpful in the treatment of patients with schizophrenia or bipolar I disorder.

Abnormal glutamate and GABA levels may underlie cognitive deficits. A recent study investigated these associations in a large group of antipsychotic-naïve patients with first-episode psychosis.

Schizophrenia is associated with an increased prevalence of alcohol use disorders. A post-hoc analysis of the clinical course of the 2 disorders is an important change in this understudied and often overlooked population.

Do neurological signs at illness onset predict long-term outcome schizophrenia?

The acute psychotomimetic effect of cannabis is transitory, but evidence indicates that the chronic use, especially if started in adolescence, contributes to the occurrence of schizophrenia.

Does cognition predict outcomes in patients at clinical high-risk for psychosis?